Gilead Sciences (GILD) 54.27 -0.805

Gilead Sciences, Inc.
(GILD) 54.27 -0.805

Last Trade:	54.27	Day Range:	53.83 - 54.90
Trade Time:	08:02PM	52wk Range:	34.45 - 56.50
Prev. Close:	55.075	Market Cap:	40.76B
Open:	54.56	Div Yield:	0
Volume:	11795921	PE:	150
EPS:	3.55

The Latest On GILD

Gilead Sciences Soars On "Striking" Clinical Trial Data 2/3/12 1:33pm

Gilead Sciences Surging on Clinical Trial Data 2/3/12 10:50am

UPDATE: JP Morgan Raises Target to $65 on Gilead Sciences 2/3/12 9:36am

Gilead Sciences up 10% Despite Lower Than Expected Q4 Profit 2/3/12 9:07am

Brean Murray Maintains Sell on Idenix 2/3/12 9:02am

UPDATE: Deutsche Bank Raises Target to $66 on Gilead Sciences 2/3/12 7:13am

JP Morgan Raises PT on Gilead Sciences to $65 2/3/12 6:59am

Brean Murray Carret & Co. Raises Gilead Sciences PT To $60 1/26/12 4:00pm

Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV 1/24/12 4:06pm

BioLineRx Surges after Hep C License Agreement 1/24/12 10:23am

Achillion's Hep C Pipeline Likely Can't Compete 1/19/12 9:03am

From Earlier: Gilead Sciences Announces U.S. Food and Drug Administration Approves New Formulations of Viread® for Use by Children Living With HIV 1/19/12 6:54am

Gilead Sciences Soars On "Striking" Clinical Trial Data 2/3/12

Gilead Sciences Surging on Clinical Trial Data 2/3/12

UPDATE: JP Morgan Raises Target to $65 on Gilead Sciences 2/3/12

Gilead Sciences up 10% Despite Lower Than Expected Q4 Profit 2/3/12

Brean Murray Maintains Sell on Idenix 2/3/12

UPDATE: Deutsche Bank Raises Target to $66 on Gilead Sciences 2/3/12

JP Morgan Raises PT on Gilead Sciences to $65 2/3/12

Brean Murray Carret & Co. Raises Gilead Sciences PT To $60 1/26/12

Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV 1/24/12

BioLineRx Surges after Hep C License Agreement 1/24/12

Achillion's Hep C Pipeline Likely Can't Compete 1/19/12

From Earlier: Gilead Sciences Announces U.S. Food and Drug Administration Approves New Formulations of Viread® for Use by Children Living With HIV 1/19/12

Gilead Sciences Soars On "Striking" Clinical Trial Data 2/3/12

6 Stocks that worth watching 1/17/12

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12

Just What The Doctor Ordered: 4 ETFs For Biotech M&A 1/9/12

Forget Dendreon, Inhibitex is the New Biotech Success Story 1/9/12

Top 4 Large-Cap Stocks In The Biotechnology Industry With The Highest Operating Margin 12/29/11

Best Biotech Stocks of 2011 12/27/11

Financial Breakfast: Morning News Summary for December 7, 2011 12/7/11

Citi Reiterates Buy, $49 PT on Gilead 12/5/11

J.P. Morgan Reiterates Overweight On Gilead 12/5/11

Brean Murray Raises Inhibitex PT to $19 From $12 11/29/11

Deutsche Bank Has Buy, $53 PT On Gilead 11/28/11

Gilead Sciences Soars On "Striking" Clinical Trial Data 2/3/12

UPDATE: JP Morgan Raises Target to $65 on Gilead Sciences 2/3/12

Brean Murray Maintains Sell on Idenix 2/3/12

UPDATE: Deutsche Bank Raises Target to $66 on Gilead Sciences 2/3/12

JP Morgan Raises PT on Gilead Sciences to $65 2/3/12

Brean Murray Carret & Co. Raises Gilead Sciences PT To $60 1/26/12

Going Nuc-lear on Hepatitis C -- Is Idenix the Next Target? 1/10/12

Citigroup Reiterates Buy, $49 Target on Gilead Sciences 12/28/11

Citigroup Reiterates Buy, $49 Target on Gilead Sciences 12/27/11

Wedbush Securities Drops Coverage on Pharmasset on Pending Gilead Acquisition 12/16/11

JP Morgan Overweight on Gilead Sciences After Pharmasset QUANTUM Trial Announcement 12/16/11

Financial Breakfast: Morning News Summary for December 7, 2011 12/7/11

Trade GILD
NOW!

Partner Headlines

Generic Challenge for UTHR's Remodulin - Analyst Blog 2/8/12

Stocks Rise On U.S. Jobs Data, Greek Debt Progress 2/7/12

3 Stocks You Shouldn't Buy Now 2/7/12

Big Bets on High-Flying Pharma Stock 2/7/12

Stock Market Today Takes A Dip As Greece Teeters 2/6/12

Stocks Down In Late Afternoon On New Greek Debt Woes 2/6/12

FDA Ponders Cancer Benefits, Risks of Amgen's Xgeva 2/6/12

Analysts' Actions: FDX, BWLD, GILD, MGM 2/6/12

Company News for February 6, 2012 - Corporate Summary 2/6/12

Analysts' Actions: FDX, BWLD, GILD, MGM 2/6/12

Gilead Sciences, Alexion Lead Surge In Biotech Stocks 2/3/12

Nasdaq Hits 11-Year High As Stocks Rally On Jobs Report 2/3/12

Press Releases

Investor Uprising IU25 Index Hits New High: Up 12% in 2012 2/8/12 Newswire Story

Critical Alerts For Disney, Gilead Sciences, Discover, Sunoco, and LG Display Released By Seven Summits Research 2/8/12 Newswire Story

Gilead Sciences Announces Fourth Quarter and Full Year 2011 Financial Results 2/2/12 Business Wire Story

Gilead Sciences to Release Fourth Quarter and Year End 2011 Financial Results on Thursday, February 2, 2012 1/27/12 Business Wire Story

Gilead Initiates Phase 2 Clinical Trial Evaluating GS-7340, A Low-Dose Novel Prodrug of Tenofovir for the Treatment of HIV 1/24/12 Business Wire Story

U.S. Food and Drug Administration Approves New Formulations of Viread® for Use by Children Living With HIV 1/18/12 Business Wire Story

Roy D. Baynes, MD, PhD, to Join Gilead Sciences as Senior Vice President, Oncology Therapeutics 1/18/12 Business Wire Story

Gilead Sciences Completes Acquisition of Pharmasset, Inc. 1/17/12 Business Wire Story

Gilead Sciences Completes Tender Offer for All Outstanding Shares of Pharmasset, Inc. 1/12/12 Business Wire Story

Gilead Sciences Announces Early Termination of Hart-Scott-Rodino Waiting Period 1/6/12 Business Wire Story

Gilead Sciences to Present at the 30th Annual JPMorgan Healthcare Conference on Monday, January 9 1/5/12 Business Wire Story

Critical Alerts for Chevron, Gilead, Medtronic, Mattel, and Mead Johnson Nutrition Released by Seven Summits Research 12/30/11 Newswire Story

Get the latest GILD stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Gilead Sciences, Inc. stock price.

Gilead Sciences, Inc. by YCharts

Gilead Sciences (GILD) 54.27 -0.805

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On GILD

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social